Verrica Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Verrica Pharmaceuticals has a total shareholder equity of $19.8M and total debt of $42.9M, which brings its debt-to-equity ratio to 216.9%. Its total assets and total liabilities are $81.6M and $61.8M respectively.
Key information
216.9%
Debt to equity ratio
US$42.87m
Debt
Interest coverage ratio | n/a |
Cash | US$69.55m |
Equity | US$19.76m |
Total liabilities | US$61.83m |
Total assets | US$81.60m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1NE's short term assets ($77.5M) exceed its short term liabilities ($17.0M).
Long Term Liabilities: 1NE's short term assets ($77.5M) exceed its long term liabilities ($44.8M).
Debt to Equity History and Analysis
Debt Level: 1NE has more cash than its total debt.
Reducing Debt: 1NE's debt to equity ratio has increased from 0% to 216.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1NE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1NE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 9.7% each year.